News from PipelinereviewFollowNews from PipelinereviewStay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today.Ground News has come across 496 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Stay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today. Ground News has come across 496 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about PipelinereviewWhere is Pipelinereview located?Pipelinereview's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top Pipelinereview NewsAlzheimerLeqembi Okayed for Subset of Early Alzheimer’s Patients100% Right coverage: 5 sourcesThe European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi (lecanemab) to treat mild cognitive impairment and early Alzheimer’s disease, following a re-examination of the clinical data. The recommendation is only for patients who have one or no copies of the apolipoprotein E4 (APOE4) gene […]See the StoryFDA · United StatesFDA Approves First Menin Inhibitor for Acute LeukemiaCoverage: 2 sourcesThe FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older withSee the StoryUnited States · United StatesDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity100% Right coverage: 1 sourcesDapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA…See the StoryLatest News StoriesTopics Most Covered by pipelinereviewVaccinesAstraZenecaMerckMedicalHealthVaccinesAstraZenecaMerckSources Covering Similar Topicsstocktitan.netClinical Trials Arenapressreach.comonclive.comPharmacy Timesstocktitan.netClinical Trials Arenapressreach.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
